Drugs / N-13 ammonia
N-13 ammonia
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 41 trial | ||||||
| Phase 4 | NCT03275584 | Jan 2018 → Jan 2028 expected | — | University of Montreal Hospital Centre (CHUM) | Recruiting | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| — | NCT01370265 Comparator | Feb 2011 → Feb 2012 | coronary artery disorder | Mayo Clinic | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | N-13 ammonia | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03275584 ↗ |
| Known as | N-13 ammoniac | “One of the substances which can be used for PET MPI is called N-13 ammoniac (NH3).” NCT03275584 ↗ |
| Known as | NH3 | “One of the substances which can be used for PET MPI is called N-13 ammoniac (NH3).” NCT03275584 ↗ |
| Modality | Diagnostic / imaging agent | “Ammonia N-13 Injection is a radioactive diagnostic agent for Positron Emission Tomography (PET) indicated for diagnostic PET imaging of the myocardium under rest or...” NCT01370265 ↗ |
| Route | Intravenous | “N-13 ammonia intravenous injection” NCT03275584 ↗ |